Evaluation of clinical practice guidelines on outcome of infection in patients in the surgical intensive care unit

Critical Care Medicine

Volumn 27, Issue 10, 1999, Pages 2118-2124

  Price, Julie ^c   Ekleberry, Ann ^a   Grover, Amelia ^c   Melendy, Susan ^c   Baddam, Kavitha ^c   McMahon, James ^a   Villalba, Mario ^a   Johnson, Matthew ^c   Zervos, Marcus J ^a,b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Antibiotics; Drug resistance; Infections; Intensive care units; Practice guidelines

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; OXACILLIN; PIPERACILLIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL PATHWAY; CONTROLLED STUDY; DEATH; DRUG COST; ESCHERICHIA COLI; FEMALE; HUMAN; INFECTION; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SURGICAL WARD;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HOSPITAL CHARGES; HOSPITALS, COMMUNITY; HOSPITALS, TEACHING; HUMANS; INTENSIVE CARE; MALE; MICHIGAN; MIDDLE AGED; PATIENT CARE MANAGEMENT; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032733792     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199910000-00007     Document Type: Article

References (60)

1. 1. Barza M: A model of the transmission of antibiotic-resistant bacteria in the intensive care unit. New Horiz 1996; 4:333-337
2. 2. American Society for Microbiology Task Force on Antibiotic Resistance: Report of the American Society for Microbiology Task Force on Antibiotic Resistance. Antimicrob Agents Chemother 1995; 39(Suppl):2-23
3. 3. Pallares R, Dick R, Wenzel RP, et al: Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978-1992). Infect Control Hosp Epidemiol 1993; 14:376-382
4. 4. Itokazu GS, Quinn JP, Bell-Dixon C, et al: Antimicrobial resistance rates among aerobic Gram-negative bacilli recovered from patients in intensive care units: Evaluation of a national postmarketing surveillance program. Clin Infect Dis 1996; 23:779-784
5. 5. Jones RN: The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens. Diagn Microbiol Infect Dis 1992; 15:3S-10S
6. 6. Martin MA: Nosocomial infections in intensive care units: an overview of their epidemiology, outcome, and prevention. New Horiz 1993; 1:162-170
7. 7. Vincent JL, Bihari DJ, Suter PM, et al: The prevalence of nosocomial infection in intensive care units in Europe. JAMA 1995; 274: 639-644
8. 8. Davis DA, Thomson MA, Oxman AD, et al: Changing physician performance. JAMA 1995; 274:700-705
9. 9. Bowen OR: Shattuck lecture - What is quality care? N Engl J Med 1987; 316:1578-1580
10. 10. Joint Commission on Accreditation of Healthcare Organizations: The Indicator Measurement System, Washington, DC, 1996
11. 11. Berwick DM: Eleven worthy aims for clinical leadership of health system reform. JAMA 1994; 272:797-802
12. 12. Kritchevsky SB, Simmons BP: Continuous quality improvement: Concepts and applications for physician care. JAMA 1991; 266: 1817-1823
13. 13. Rizzo JA, Sindelar JL: Medical practice guidelines and the efficient allocation of resources. In: Health Care Policy and Regulation. Abbott TA (Ed). New York, Kluwer Academic, 1995. pp 182-199
14. 14. Pearson SD, Goulart-Fisher D, Lee TH: Critical pathways as a strategy for improving care: Problems and potential. Ann Intern Med 1995; 123:941-948
15. 15. Hyams AL, Brandenburg JA, Lipsitz SR, et al: Practice guidelines and malpractice litigation: A two-way street. Ann Intern Med 1995; 122:450-455
16. 16. Sox HC: Practice guidelines: 1994. Am J Med 1994; 97:205-207
17. 17. Ellrodt AC, Conner L, Riedinger M, et al: Measuring and improving physician compliance with clinical practice guidelines. Ann Intern Med 1995; 122:277-282
18. 18. Shane R: Development and implementation of practice guidelines. Hosp Formul 1994; 29:711-719
19. 19. Horn S, Hopkins DS: Clinical Practice Improvement: A New Technology for Developing Cost-Effective Health Care. New York, Faulkner and Gray, 1992, p 1
20. 20. Spath PL: Clinical paths - Tools for outcomes management. Chicago, American Hospital Association, 1994
21. 21. Fliegelman R: Development of a clinical algorithm using continuous quality improvement. Pharmacol Ther 1996; 275:490-501
22. 22. Schriefer J: The synergy of pathways and algorithms: Two tools work better than one. Jt Comm J Qual Improve 1994; 20:485-499
23. 23. Bohnen JMA, Solomkin JS, Dellinger P, et al: Guidelines for clinical care: Anti-infective agents for intra-abdominal infection. Arch Surg 1992; 127:83-89
24. 24. Harris JM Jr: Disease management: New wine in new bottles? Ann Intern Med 1996; 124:838-842
25. 25. Epstein RS, Sherwood LM: From outcomes research to disease management: A guide for the perplexed. Ann Intern Med 1996; 124: 832-837
26. 26. Garner JS, Jarvis WR, Emori TG, et al: CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-140
27. 27. Department of Health and Human Services Centers for Disease Control and Prevention: Spreading the spread of vancomycin resistance - Report from the hospital infection control practices advisory committee; comment period and public meeting; notice. Federal Register 1994; 59:25758-25763
28. 28. Knaus WA, Wagner DP, Draper EA, et al: The APACHE III prognostic system*: Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100:1619
29. 29. Couch JB, Nash DB: Severity of illness measures: Opportunities for clinicians. Ann Intern Med 1988; 109:771-773
30. 30. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Second Edition. Approved standard. NCCLS document M7-A2. Villanova, PA, National Committee for Clinical Laboratory Standards, 1990.
31. 31. Buckwold FJ, Ronald AR: Antimicrobial misuse-effects and suggestions for control. J Antimicrob Chemother 1979; 5:129-136
32. 32. Jacobson KL, Cohen SH, Inciardi JF, et al: The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporin in group I â-lactamase-producing organisms. Clin Infect Dis 1995; 21:1107-1113
33. 33. Muder RR, Brennen C, Goetz AM, et al: Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among Gram-negative isolates in a Veterans Affairs medical center. Antimicrob Agents Chemother 1991; 35:256-258
34. 34. Chow JW, Fine MJ, Shlaes DM, et al: Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 8:585-590
35. 35. Schaberg DR, Rubens CE, Alford RH, et al: Evolution of antimicrobial resistance and nosocomial infection. Am J Med 1981; 70: 445-448
36. 36. Schaberg DR, Culver DH, Gaynes RP: Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 91(Suppl 3B):72S-75S
37. 37. Pinner RW, Teutsch SM, Simonsen L, et al: Trends in infectious diseases mortality in the United States. JAMA 1996; 275:189-193
38. 38. Jarvis WR: Preventing the emergence of multidrug-resistant microorganisms through antimicrobial use controls: The complexity of the problem. Infect Control Hosp Epidemiol 1996; 17:490-495.
39. 39. North D: Controlling the costs of antibiotic resistance. Clin Ther 1993; 15:3-11
40. 40. Lederberg J, Shope RE, Oaks SC (Eds): Emerging Infections: Microbial Threats to Health in the United States. Washington, DC, National Academy Press, 1992, p 94
41. 41. U.S. Department of Health and Human Services: Healthy people 2000: National health promotion and disease prevention objectives. Washington, DC, U.S. Government Printing Office, 1990, p 526.
42. 42. Centers for Disease Control and Prevention: Addressing emerging infectious disease threats: A prevention strategy for the United States. MMWR Morb Mortal Wkly Rep 1994; 43:1-18
43. 43. Leibovici L, Konisberger H, Pitlik SD, et al: Patients at risk for inappropriate antibiotic treatment of bacteremia. J Intern Med 1992; 231:371-374
44. 44. Archibald L, Phillips L, Monnet D, et al: Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit. Clin Infect Dis 1997; 24:211-215
45. 45. McGowan JE Jr: Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Contrl Hosp Epidemiol 1994; 15:478-483
46. 46. Goldmann DA, Weinstein RA, Wenzel RP, et al: Strategies to prevent and control the emergence and spread of antimicrobial resistant microorganisms in hospitals. JAMA 1996; 275:234-240
47. 47. Schentag JJ, Ballow CH, Fritz AL, et al: Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the Infectious Disease Division, and the Microbiology Laboratory. Diagn Microbiol Infect Dis 1993; 16:255-264
48. 48. Anglim A, Klym B, Byers KE, et al: Effect of a vancomycin restriction policy on ordering practices during an out-break of vancomycin resistant Enterococcus faecium. Arch Intern Med 1997; 157:1132-1136
49. 49. Gaynes R: Antibiotic resistance in ICUs: A multifaceted problem requiring a multifaceted solution. Infect Control Hosp Epidemiol 1995; 16:328-330
50. 50. Hoppe B: Control of infections caused by drug-resistant organisms in critical care. Am J Crit Care 1997; 6:141-144
51. 51. Schentag JJ, Paladino JA, Birmingham MC, et al: Use of benchmarking techniques to justify the evolution of antibiotic management programs in healthcare systems. J Pharm Technol 1995; 11:203-210
52. 52. Evans RS, Burke JP, Classen DC, et al: Computerized identification of patients at high risk for hospital-acquired infection. Am J Infect Control 1992; 20:4-10
53. 53. Johnston ME, Langton KB, Haynes RB, et al: Effects of computer-based clinical decision support systems on clinician performance and patient outcome. Ann Intern Med 1994; 120:135-142
54. 54. Johnson N, Last J: Understanding and using technology assessments. Pharmacol Ther 1995; 35:477-486
55. 55. Hedblom EC: Pharmacoeconomic and outcomes data in the managed care formulary decision-making process. Pharmacol Ther 1995; 462-473
56. 56. Bankowitz RA, McNeil MA, Challinor SM, et al: A computer-assisted medical diagnostic consultation service. Ann Intern Med 1989; 110:824-832
57. 57. Classen DC: Information management in infectious diseases: survival of the fittest. Clin Infect Dis 1994; 19:902-909
58. 58. Pestotnik SL, Classen DC, Evans RS, et al: Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes. Ann Intern Med 1996; 124:884-890
59. 59. Brooks A, Ekleberry A, McMahon J, et al: Evaluation of clinical practice guidelines on rates of nosocomial infection in intensive care unit patients. 36th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC). New Orleans, LA, May 1996.
60. 60. Seppälä H, Llaukka T, Vuopio-Varkila J, et al: The effect of changes in consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337:441-446